Tha Clarus Kerfuffle...When Atkinson at Clarus lowered his price target to $1.25, he believed that SZLS had abandoned the "employer group testing" market. Tripp quickly corrected that, but many didn't pause to listen. The ensuing weeks-long short attack left a huge gap between current share price and actual value.
Which creates an opportunity now... It's clear that StageZero is very actively pursuing the employer market, and has other healthcare interests, such as; StayWell in Florida bringing patients into the fold.
With Aristotle's unparallelled accuracy as a multi-cancer diagnostic test,(better than Grail's multi-billion dollar "Galieri" test) it won't be long before that market has been addressed by SZLS.
It's such a brilliant business plan that even Grail are doing the same.
So, Atkinson's $1.25 price target probably needs an upward revision.
But don't expect it until after the next financials.
Investment analysts' main strength is their reputation, and no one wants to admit they overreacted, IMHO.